Page 1 of 40
Photobiomodulation (PBM), which utilizes specific light wavelengths to regulate cellular metabolism, signal transduction, and gene expression, has emerged as a promising intervention for enhancing cognitive fu...
Both electroacupuncture (EA) and repetitive transcranial magnetic stimulation (rTMS) possess the potential in combating the progression of Alzheimer’s disease (AD). In this study, we compared the effects of th...
Edaravone-Dexborneol (EDB) presents therapeutic effects due to its anti-inflammatory, antioxidant and anti-apoptotic properties, and has been widely used in ischemic stroke. However, the detailed efficacy and ...
Emerging evidence suggests that senescent microglia play a role in β-amyloid (Aβ) pathology and neuroinflammation in Alzheimer’s disease (AD). Targeting senescent cells with naturally derived compounds exhibit...
Plasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney function, which could impact the interpretation of ATN biomarker results, particularly in grou...
Age-related macular degeneration (AMD) is the commonest cause of irreversible blindness in developed societies. AMD coincides with advanced age to which genetic and lifestyle factors contribute additional risk...
A proteome-wide association study (PWAS) that integrates proteomic data with genome-wide association study (GWAS) summary data is a powerful tool for studying Alzheimer’s disease (AD) dementia. Existing PWAS a...
Event-based modeling (EBM) traces sequential progression of events in complex processes like neurodegenerative diseases, adept at handling uncertainties. This study validated an EBM for Alzheimer’s disease (AD...
The growing prevalence of dementia emphasizes the need for effective prevention strategies. Although the partial efficacy of multidomain interventions for dementia prevention has been demonstrated, understandi...
Agitation is one of the most prevalent neuropsychiatric symptoms leading to institutionalization in individuals with Alzheimer’s disease (AD) dementia. It is associated with poor outcomes, including reduced fu...
Dysregulation retrograde axonal transport in neurons results in autophagosome accumulation, enhancing amyloid β (Aβ) production and accelerating Alzheimer’s disease (AD) progression. Ras-associated GTP-binding...
Plasma biomarkers offer a promising alternative to amyloid beta (Aβ) positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers for diagnosing Alzheimer’s disease (AD). This cross-sectional stu...
Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials with...
Emerging evidence indicates that globus pallidus (GP) function can be modulated by orexin-A in movement disorders, while its role in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) remains unclear...
The adenosine monophosphate-activated protein kinase (AMPK) and its downstream effector Unc-51 like autophagy activating kinase 1 (ULK1) represent a key cellular signaling node, the alteration of which likely ...
Magnetic resonance imaging (MRI), combined with artificial intelligence techniques, has improved our understanding of brain structural change and enabled the estimation of brain age. Neurodegenerative disorder...
The diagnosis of Alzheimer’s disease (AD) in its preclinical stages, such as subjective cognitive decline (SCD), is crucial for a timely management of the condition. However, current early diagnostic methods a...
Although previous studies have shown that specific platelet indices had correlations with cognitive impairment, the associations between platelet indices and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s...
Alzheimer’s disease and related dementias (ADRD) take 20 to 30 years to develop, yet setting up studies or registries that take into account the entire disease trajectory is difficult and time consuming. Moreo...
Emerging evidence highlights the bidirectional communication between the gut microbiota and the brain, suggesting a potential role for gut dysbiosis in Alzheimer’s disease (AD) pathology and cognitive decline....
The hippocampus is highly affected in neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The relationship between neuropathology and atrophy in hippocampal subfields i...
Cognitive impairment, hypertension and diabetes are prevalent chronic conditions in populations of older ages. Previous studies have shown that hypertension and diabetes are risk factors for the development of...
Lecanemab, a monoclonal antibody targeting amyloid beta, has recently been approved for treatment of early-stage Alzheimer’s disease (AD), demonstrating amyloid plaque reduction and slowing of cognitive declin...
The rapidly progressive phenotype of Alzheimer’s disease (rpAD) remains a rare and less-studied entity. Therefore, the replication of key results from the rpAD brain and cerebrospinal fluid (CSF) is lacking.
Dementia with Lewy bodies (DLB) is associated with specific challenges, including heterogeneity in clinical presentation and a less favourable prognosis relative to other dementia subtypes. These challenges ne...
Anti-amyloid antibodies for the treatment of Alzheimer´s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health car...
Synaptic dysfunction is a relevant feature of Alzheimer’s disease (AD) and Parkinson’s disease (PD) and can be quantified through the measurement of cerebrospinal fluid (CSF) synaptic markers, such as the pres...
New drugs to treat Alzheimer´s disease (AD) are urgently needed. Human triggering receptor expressed on myeloid cells 2 (hTREM2) is a validated drug target which is genetically associated with AD. Existing ant...
The original article was published in Alzheimer's Research & Therapy 2025 17:86
The use of polygenic risk scores (PRS) for predicting disease risk in Japanese populations, particularly for dementia and related phenotypes, remains markedly unexplored. The aim of this study was to bridge th...
Movement patterns, activity levels and circadian rhythm are altered in Alzheimer’s disease (AD) and can be assessed by actigraphy using wearable sensors. We aimed to determine the diagnostic performance of act...
The original article was published in Alzheimer's Research & Therapy 2025 17:26
Cannabidiol (CBD), the second most abundant phytocannabinoid in Cannabis sativa, has garnered significant interest due to its non-psychoactive nature and diverse receptor interactions.
Epidemiological and clinical studies have reported an association between leukocyte telomere length (LTL) and Alzheimer’s disease (AD). However, genetic association between the two phenotypes remains largely u...
Exploring the early stages of Alzheimer's disease (AD) is crucial for timely intervention to help manage symptoms and set expectations for affected individuals and their families. However, the study of the ear...
Mild cognitive impairment (MCI) is a heterogeneous disorder with significant individual variabilities in clinical and biological features. Abnormal inter-regional structural covariance suggests disruption of t...
Hyperexcitability in Alzheimer’s disease (AD) is proposed to emerge early and contribute to disease progression. The dentate gyrus (DG) and its primary cell type, granule cells (GCs) are implicated in hyperexc...
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder clinically characterized by memory decline, cognitive dysfunction, language impairment, deterioration of visuospatial skills, and p...
Depression serves as a prodromal symptom of dementia, and individuals with depression exhibit a significantly higher risk of developing dementia. The aim of this study is to develop and validate a novel dement...
Oxysterols, gut metabolites, and N6-methyladenosine (m6A) are extensively implicated in the pathogenesis of cognitive dysfunction, while their alterations in different stages of mild cognitive impairment (MCI)...
Cognitive frailty (CF) in older adults is a potentially reversible syndrome that may benefit from lifestyle-based multidomain interventions. This study assessed the AGELESS intervention’s impact on cognitive, ...
The SorLA protein, encoded by the Sortilin-related receptor 1 (SORL1) gene, is a major player in Alzheimer’s disease (AD) pathophysiology. Functional studies demonstrated that SorLA deficiency results in increase...
Onset-predictive biomarker tests (OPBT) in genetic frontotemporal dementia (FTD) may be used to recruit mutation carriers into preventive clinical trials before symptoms manifest. This would require disclosure...
The pathological effects of amyloid β oligomers (Aβo) may be mediated through the metabotropic glutamate receptor subtype 5 (mGluR5), leading to synaptic loss in Alzheimer’s disease (AD). Positron emission tom...
Emerging evidence supports the diagnostic and prognostic utility of plasma biomarkers in Alzheimer’s disease (AD), particularly in early disease stages. We sought to extend these findings by evaluating the pro...
Mutations in the presenilin 1 gene (PSEN1) are well-known causes of early-onset familial Alzheimer’s disease, but they can also present with atypical phenotypes such as pure spastic paraparesis. This study aims t...
The ubiquitin-proteasome system (UPS) is responsible for most protein degradation and its malfunction is normally observed in neurodegenerative diseases, including Alzheimer’s disease (AD). The autocrine motil...
Emerging evidence implicates early dysfunction of dopaminergic neurons in the Ventral Tegmental Area (VTA) as a key contributor to Alzheimer’s Disease (AD) pathophysiology. Specifically, the VTA dopaminergic n...
In Alzheimer’s disease (AD), MRI atrophy patterns can distinguish between amnestic (typical) and non-amnestic (atypical) clinical phenotypes and are increasingly used for diagnosis and outcome measures in clin...
A recent paper published a lecanemab analysis with data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. While the authors mention the limitations of F...
Alzheimer's Research & Therapy